Pharma: Covid-19 R&D and Product Pipeline
We detail ongoing efforts by Pharma companies on Covid-19, going beyond vaccine development to cover those that are developing test kits and treatment drugs.
Read moreVanda Announces Positive Pivotal Study Results for HETLIOZ® (tasimelteon) in Patients with Smith-Magenis Syndrome
Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that HETLIOZ® (tasimelteon) improved sleep quality and increased sleep duration in patients with Smith-Magenis Syndrome (SMS) in a pivotal placebo controlled clinical...
Read moreREGENTYS CORPORATION: Binding Letter of Intent
This letter agreement sets forth our agreement and understanding as to the essential terms of the sale to Generex Biotechnology Corporation, Delaware corporation (or an affiliate thereof) (the Purchaser) by Regentys Corporation, A Florida...
Read moreNavidea Biopharmaceuticals Appoints Dr. Michael Rosol as Chief Medical Officer
Company today announced the appointment of Michael Rosol, PhD as Chief Medical Officer of Navidea, effective December 17. We are pleased for Dr. Rosol to join Navidea and bring his deep insights into the needs of the industry for the development...
Read morePhoenix Life Sciences International Receives Approval for Name Change, Symbol Change, and Completion of Consolidation of Businesses
Phoenix Life Sciences International Limited (OTC: PLSI) (Phoenix Life), an international adaptive healthcare solutions company, today announced it has completed the last stages the consolidation of businesses and received approval from the...
Read morePhoenix Life Sciences Receives Import Certificate for Cannabis Diabetes Drug from the Republic of Vanuatu
Phoenix Life Sciences International Limited (OTCMarkets: PLSI) (Phoenix Life), an international adaptive healthcare solutions company, today announced that it has received an import certificate from the Republic of Vanuatus Minister of Health to...
Read morePhoenix Life Sciences International Announces Significant Retirement of Convertible Debt and Elimination of Outstanding Preferred Shares
Phoenix Life Sciences International Limited (Phoenix Life) (OTC: PLSI), an international adaptive healthcare solutions company, today announced that it has retired additional convertible debt, positioning the company with no more outstanding...
Read moreMEDIFIRST SOLUTIONS ANNOUNCES NEW AGREEMENT FOR CBD PRODUCTS AND DISTRIBUTION
MEDIFIRST SOLUTIONS, INC. (OTC: MFST) (the Company or Medifirst), a provider of innovative laser technology with its FDA 510(k) cleared Infrared Time Machine TTML-8102000 Laser Thermal Therapeutic Device and a provider of Specialty Pharmacy Drug...
Read moreOPGEN REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
OpGen, Inc. (NASDAQ: OPGN) today reported financial and operating results for the three and nine months ended September 30, 2018 and provided a business update. Total revenue for the third quarter of 2018 was $0.6 million, compared with $0.7...
Read moreHEAT BIOLOGICS, INC. PRICES $12,000,000 PUBLIC OFFERING
Durham, NC November 21, 2018 Heat Biologics, Inc. (Heat) (NASDAQ: HTBX), a biopharmaceutical company developing immunotherapies with the goal of activating a patients immune system against cancer through T-cell activation, today announced the...
Read moreFuse Medical, Inc. Ranked No. 56 Fastest Growing Company in North America on Deloittes 2018 Technology Fast 500 TM
Fuse Medical, Inc., (OTC: FZMD), (Fuse or the Company), a contract manufacturer and national distributor of medical devices, announced that it has been named Number 56 on Deloittes 2018 Technology Fast 500 TM (Technology Fast 500 TM), an annual...
Read moreBIOPHARMX CORPORATION WARRANT TO PURCHASE COMMON STOCK
[Read on via official release] Source: US SECView full document:8-K_for_BioPharmX_Corp_8-K-11-21-2018
Read more